Patent Oppositions in medicinal compounds for specific treatments industry

Explore the competitive field of medicinal compounds for specific treatments where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in medicinal compounds for specific treatments technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Last updated on: Sep 17, 2026
CompanyTotal Oppositions
NOVARTIS366
BOEHRINGER INGELHEIM174
F HOFFMANN LA ROCHE104
PFIZER98
NOVO NORDISK92
NUTRICIA92
AMGEN89
BRISTOL MYERS SQUIBB82
NESTLE82
NESTEC73

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the medicinal compounds for specific treatments industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the medicinal compounds for specific treatments industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Sep 17, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Formulation For Anti-Alpha4Beta7 AntibodyMILLENNIUM PHARMACEUTICALSSep 10, 2026CAMULON
Composition For Enteral IntakeMORINAGA MILK INDUSTRYSep 9, 2026FRESENIUS KABI DEUTSCHLAND
Methods Of Treating Fabry Patients Having Renal ImpairmentAMICUS THERAPEUTICSSep 9, 2026MAIWALD PATENTANWALTS
Formulation For Anti-Alpha4Beta7 AntibodyMILLENNIUM PHARMACEUTICALSSep 9, 2026FRESENIUS KABI SWISSBIOSIM
Stable, Concentrated Radionuclide Complex SolutionsADVANCED ACCELERATOR APPLICATIONSSep 9, 2026LUMARA BIO ONCOLOGICS
Stable, Concentrated Radionuclide Complex SolutionsADVANCED ACCELERATOR APPLICATIONSSep 9, 2026LUMARA BIO ONCOLOGICS
Stable, Concentrated Radionuclide Complex SolutionsADVANCED ACCELERATOR APPLICATIONSSep 9, 2026LUMARA BIO ONCOLOGICS
Methods Of Treating Fabry Patients Having Renal ImpairmentAMICUS THERAPEUTICSSep 8, 2026TEVA PHARMACEUTICAL INDUSTRIES LTD
Methods Of Treating Fabry Patients Having Renal ImpairmentAMICUS THERAPEUTICSSep 8, 2026TEVA PHARMACEUTICAL INDUSTRIES LTD
Formulation For Anti-Alpha4Beta7 AntibodyMILLENNIUM PHARMACEUTICALSSep 4, 2026ABEL & IMRAY

To stay ahead in the competitive medicinal compounds for specific treatments industry, companies are constantly innovating. Here are the top patents facing oppositions in the medicinal compounds for specific treatments industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Sep 17, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS23
Apr 14, 2021Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY22
Nov 6, 2024Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICA20
Nov 26, 2025Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or HyperglycemiaBOEHRINGER INGELHEIM19
Oct 23, 2024New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTIS19
Aug 6, 2025Use Of Long-Acting Glp-1 PeptidesNOVO NORDISK18
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM18
Mar 8, 2023Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTIS17
Oct 11, 2023New UseNOVARTIS16
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE15